Mr Junien has experience both in Europe and in the US in managing preclinical and clinical developments. Mr Motesharei is a former biotech executive with over 10 years of experience in pharmaceutical and biotechnology industry.
Jean-Francois Mouney, chairman and CEO of Genfit, said: “It’s a great honor and a fantastic opportunity to welcome Jean-Louis Junien and Kia Motesharei. Their experiences and their acumen are strong assets for the company.”
Mr Junien said: “Genfit impressed me for several reasons. On the scientific level, the thorough knowledge of its teams, whose biological approach is firmly anchored in the genomic and the proteomic, constitutes a major competing advantage.
“On the industrial side, the company’s business model simultaneously based on partnerships agreements with the largest players of pharmaceutical industry and a robust pipeline of innovative proprietary products appeared extremely attractive to me. I’m looking forward to take part in the future successes of Genfit’s drug candidates.”